Which are the most successful innovative companies in the world in 2016?
Bringing something new to the table is something that seems to be difficult these days, considering that many things have already been done, have already been invented, and have already been brought to the spotlight. Thus, figuring out which are the 10 most successful innovative companies in the world in 2016 is not an easy feat.
Awhile back, Forbes published research from the Innovator’s DNA, which is the result of an eight-year collaborative study during which nearly a hundred inventors of revolutionary products and services were interviewed, alongside founders and CEOs. The goal was to find those companies that innovate the most and bring something new to the world.
The companies are ranked by something called their “innovation premium”, which is the difference between their market caps and the net present value of cash flows from their existing businesses. Thus, the list is as much about companies that could be innovative in the future as opposed to ones which were innovative in the past (though both would naturally apply to many companies, short of a drastic change in managerial direction at some point in the past). To be on this list, firms needed to have at least seven years of public financial data and $10 billion in market cap. While you may not find companies that you think would be obvious members of this list, there are still names that are part of industries that are known to invest in innovation.
Without further ado, here are the 10 most successful innovative companies in the world in 2016.
10. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Innovation Premium – 64.7%
Market Cap – $15.2 billion
If the name didn’t give it away, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a pharmaceutical company which delves into the fields of biotechnology and life sciences. It has a market cap of over $15 billion and was founded nearly 20 years ago, in 1997, with its headquarters in California.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is known for developing and selling medications for various diseases and medical conditions that are life-threatening. For instance, Naglazyme was created to fight against MPS VI (Mucopolysaccharidosis VI), which is a disorder that threatens lysosomal storage through a deficiency of an enzyme that is needed for the breakdown of certain carbs.
BioMarin is one of the most popular biotechs among the group of successful hedge funds tracked by Insider Monkey, several of which are focused exclusively on the healthcare sector. 42 funds in our system were long BioMarin on June 30, owning 11.90% of its shares. The largest position among them (4.81 million shares) was held by healthcare investing gurus Julian Baker and Felix Baker of Baker Bros. Advisors.